Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Elanco Animal Health Incorporated
ELAN
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $12.0B
$24.80
▲ +2.93%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$13.39 - $27.72
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 63.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Strong brand portfolio with market-leading products recognized globally by veterinarians and consumers
- Integrated manufacturing and distribution network serving multiple customer channels
- Diversified revenue base across companion animals and production agriculture reduces cyclical risk
- Established relationships with veterinary professionals and agricultural producers
Bear Case
2 risks
- Above-average volatility (beta 1.7).
- Premium valuation to Large Cap Pharma peers
Growth
Turning profitable
Increasing global pet ownership and spending on pet healthcare
Value
Premium valuation to Large Cap Pharma peers
Momentum
Stable
+4.4% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ELAN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 6, 2026
MAY 6, 2026
Reported EPS of $0.40 vs $0.34 consensus (+17.6% surprise). Revenue of $1.4B vs $1.3B expected (+7.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+17.6%
Next: Aug 6, 2026
Revenue trend · last 8Q
—
—
—
-1%
+5%
+10%
+12%
+15%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$1.2B
$1.0B
$1.0B
$1.2B
$1.2B
$1.1B
$1.1B
$1.4B
Margins · last 8Q
Gross
—
Operating
—
Profit
4.2%
Wall Street consensus
7 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
$23.00
▼ -7.2% vs $24.80
Latest: Piper Sandler · Jun 29, 2026
1 analyst covering
vs Industry
How ELAN stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related